Spruce Biosciences, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Spruce Biosciences, Inc. (SPRB) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$28.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2022-11-10
- Spruce Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2022-09-30 was -$28.00K, a 315.38% decline year-over-year.
- Spruce Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2022-06-30 was -$152.00K.
- Spruce Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2022-03-31 was -$509.00K.
- Spruce Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2021-12-31 was -$168.00K.
- Spruce Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2021 was -$184.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$28.00K 10-Q · filed 2022-11-10 | -$180.00K derived: sum of 2 quarters · filed 2022-11-10 | -$689.00K 10-Q · filed 2022-11-10 | -$857.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | -$152.00K 10-Q · filed 2022-08-10 | -$661.00K 10-Q · filed 2022-08-10 | -$829.00K derived: sum of 3 quarters · filed 2022-08-10 | -$816.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | -$509.00K 10-Q · filed 2022-05-11 | -$677.00K derived: sum of 2 quarters · filed 2022-05-11 | -$664.00K derived: sum of 3 quarters · filed 2022-11-10 | -$693.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | -$168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$155.00K derived: sum of 2 quarters · filed 2022-11-10 | -$184.00K derived: sum of 3 quarters · filed 2022-11-10 | -$184.00K 10-K · filed 2022-03-14 |
| 2021-09-30 | $13.00K 10-Q · filed 2022-11-10 | -$16.00K derived: sum of 2 quarters · filed 2022-11-10 | -$16.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$29.00K 10-Q · filed 2022-08-10 | -$29.00K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |